Exact Sciences Corporation is a global leader in cancer diagnostics and screening, focused on preventing, detecting, and treating cancer through innovative molecular diagnostic solutions. Founded in 1995 in Marlborough, Massachusetts, the company has grown to employ approximately 6,500 people and operates in over 120 countries. Its mission emphasizes early cancer detection and prevention, guided by core values of innovation, integrity, quality, teamwork, and accountability.
The company offers a diverse range of cancer diagnostic tests, including Cologuard®, a non-invasive stool DNA test for colorectal cancer, and the Oncotype DX Breast Recurrence Score® test for genomic assessment. Recent additions to their portfolio include the OncoExTra® cancer therapy selection test and a Multi-cancer Earlier Detection (MCED) test. Exact Sciences has expanded its capabilities through strategic acquisitions, enhancing its personalized cancer diagnostics and broadening its test offerings. Headquartered in Madison, Wisconsin, the company is committed to advancing cancer care and has been recognized as a Great Place To Work for seven consecutive years.
23andMe Holding Co is a consumer-facing healthcare technology company, primarily involved in the sale of direct-to-consumer personal genome services, or PGS, through DNA collection kits shipped via mail. The company provides users access to reports summarizing estimated genetic ancestry breakdown, phenotypic trait reports, and various health predisposition and disease carrier reports. Its segment includes Consumer and Research Services and Therapeutics. The company generates maximum revenue from the Consumer and Research Services segment.